New hope for lymphoma patients: drug combo trial launches

NCT ID NCT06082102

Recruiting now Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether a combination of orelabrutinib and rituximab works better than lenalidomide plus rituximab for people with marginal zone lymphoma that has come back or not responded to treatment. About 324 adults will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib and rituximab
What this could lead to: If successful, this could offer a new, more effective treatment option for people with marginal zone lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is a phase 3 trial, but results are not yet known. The experimental combination may not prove better than the standard combination, and side effects like infections or blood cell changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100070, China
Beijing Tongren Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100730, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Guangdong Provincial Hospital of Chinese Medicine
RECRUITING

Guangzhou, Guangdong, 510120, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Henan Provincial Peoples Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410000, China
Jiangxi Cancer Hospital
RECRUITING

Nanchang, Jiangxi, 330029, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510055, China
The Affiliated Hospital Of Qingdao University
NOT_YET_RECRUITING

Qingdao, Shandong, 266000, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, Auhui, 233000, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
The Second Affiliated Hospital of Xi'an Jiaotong University（Xibei Hospital）
RECRUITING

Xi’an, Shanxi, 710004, China
The Second Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, 116023, China
The first Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110002, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, 264099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.